The new cells prevented the onset of diabetes in an animal model of the disease bringing personalized cell therapy for diabetes closer.
Scientists at the Gladstone Institutes and the University of California, San Francisco (UCSF) have successfully converted human skin cells into fully-functional pancreatic cells. The new cells produced insulin in response to changes in glucose levels, and, when transplanted into mice, the cells protected the animals from developing diabetes in a mouse model of the disease.
The new study, published in Nature Communications, also presents significant advancements in cellular reprogramming technology, which will allow scientists to efficiently scale up pancreatic cell production and manufacture trillions of the target cells in a step-wise, controlled manner. This accomplishment opens the door for disease modeling and drug screening and brings personalized cell therapy a step closer for patients with diabetes.
“Our results demonstrate for the first time that human adult skin cells can be used to efficiently and rapidly generate functional pancreatic cells that behave similar to human beta cells,” says Matthias Hebrok, PhD, director of the Diabetes Center at UCSF and a co-senior author on the study. “This finding opens up the opportunity for the analysis of patient-specific pancreatic beta cell properties and the optimization of cell therapy approaches.”
In the study, the scientists first used pharmaceutical and genetic molecules to reprogram skin cells into endoderm progenitor cells—early developmental cells that have already been designated to mature into one of a number of different types of organs. With this method, the cells don’t have to be taken all the way back to a pluripotent stem cell state, meaning the scientists can turn them into pancreatic cells faster. The researchers have used a similar procedure previously to create heart, brain, and liver cells.
After another four molecules were added, the endoderm cells divided rapidly, allowing more than a trillion-fold expansion. Critically, the cells did not display any evidence of tumor formation, and they maintained their identity as early organ-specific cells.
The scientists then progressed these endoderm cells two more steps, first into pancreatic precursor cells, and then into fully-functional pancreatic beta cells. Most importantly, these cells protected mice from developing diabetes in a model of disease, having the critical ability to produce insulin in response to changes in glucose levels.
“This study represents the first successful creation of human insulin-producing pancreatic beta cells using a direct cellular reprogramming method,” says first author Saiyong Zhu, PhD, a postdoctoral researcher at the Gladstone Institute of Cardiovascular Disease. “The final step was the most unique—and the most difficult—as molecules had not previously been identified that could take reprogrammed cells the final step to functional pancreatic cells in a dish.”
Sheng Ding, PhD, a senior investigator in the Roddenberry Stem Cell Center at Gladstone and co-senior author on the study, adds, “This new cellular reprogramming and expansion paradigm is more sustainable and scalable than previous methods. Using this approach, cell production can be massively increased while maintaining quality control at multiple steps. This development ensures much greater regulation in the manufacturing process of new cells. Now we can generate virtually unlimited numbers of patient-matched insulin-producing pancreatic cells.”
The Latest on: Personalized cell therapy
via Google News
The Latest on: Personalized cell therapy
- Liquid Biopsy Assay Identifies Responses to Neoadjuvant Therapy in Early-Stage Breast Canceron September 6, 2019 at 1:45 pm
This personalized approach to blood analysis could be a reliable approach in the future for identifying curative responses to neoadjuvant therapy before a patient ... which could make cell-free DNA.
- Dr. Wang on Combatting CAR T-Cell Therapy Resistance in MCLon September 6, 2019 at 9:41 am
CD19-targeted CAR T-cell therapy can put some patients with MCL into long-term ... resistance in each patient and then target this pathway to overcome resistance in a personalized fashion, concludes ...
- Cancer Gene Therapy Market Growth Opportunities, Trends by Manufacturers, Regions, Application and Forecast to 2024on September 6, 2019 at 8:24 am
rising cancer prevalence will increase demand for gene therapy as the effective personalized treatment choice. According to WHO, cancer incidence is projected to rise by 50% to reach 15 million by the ...
- Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatmenton September 5, 2019 at 9:55 pm
and defer the need for costly treatments such as radiation therapy or surgery, which can cause side effects or other problems. The study was published in the journal Personalized Medicine.
- Achilles Therapeutics raises $120M in Series B round for cancer cell therapyon September 4, 2019 at 9:16 am
Achilles’ approach involves personalized T-cell therapies that ... scientific and clinical knowledge from immuno-oncology, cell therapy and genomics with the goal of creating a TIL-based ...
- Meeting the Challenge of Gene Therapy Manufacturingon September 4, 2019 at 6:43 am
To meet demand worldwide, manufacturers will need custom platforms designed with gene therapy in mind. Existing equipment and ... For instance, host cell DNA and proteins are released when the cells ...
- UK Biotech’s Personalized Immunotherapy gets €110M Series B Booston September 3, 2019 at 6:56 am
The UK company Achilles Therapeutics has raised €110M (£100M) to test its personalized cancer cell immunotherapies ... as well as scale up its cell therapy manufacturing facilities. Achilles’ cell ...
- North America Uterine Cancer Diagnostics & Treatment Market Report 2019-2024 - ResearchAndMarkets.comon August 28, 2019 at 10:30 am
Recent breakthroughs have led to many advances in personalized approaches to various cancer types ... non-specific immunotherapies, oncolytic virus therapy, T-cell therapy, and cancer vaccines.
- Gold nanoparticles shown to be safe and effective treatment for prostate canceron August 27, 2019 at 9:38 am
AuroShells® are designed to absorb energy from near-infrared light and convert it to heat, resulting in selective hyperthermic cell death, without affecting adjacent non-tumorous tissue. The treatment ...
- Cellular therapy CDMO Cognate closes growth capital roundon August 27, 2019 at 7:03 am
According to Cognate, it is one of the only CDMOs capable of handling the volume of personalized products that are being ... cellular immunotherapy, and cell therapy companies. The company has ...
via Bing News